The authors discuss how aberrant expression of C-X-C motif chemokine 12 (CXCL12)/C-X-C chemokine receptor type 4 (CXCR4) and CXCL12/CXCR7 pathways might regulate leukemogenesis and end by outlining the key news of preclinical and clinical investigations in leukemia treatment.
[European Journal of Pharmacology]